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Background:Novel serologicalmethodsprovide alternativeoptions for sero-diagnosis, sero-epidemiology
and for determining evidence of naturally acquired or vaccine induced immunity. Micro-neutralization
tests are currently the gold standard for serological studies of highly pathogenic avian influenza in mam-
malian species but require handling live virus in a biosafety level (BSL) 3 environment. We previously
reported the use of H5 pseudotyped lentiviral particles (H5pp) as an alternative to micro-neutralization
tests in a BSL-2 setting (Nefkens et al., 2007).





Study design: We optimise and evaluate the performance of the H5pp assay using well-characterized sera
from humans with confirmed H5N1 disease or controls.
Results:TheH5ppassay is a reliable serologicalmethod for thedetectionandquantificationofneutralizing
antibody to H5-viruses.
e a re
2 setConclusion: H5pp provid
H5N1 infections in a BSL-
. Background
Assessment of the sero-prevalence to potentially pandemic
ighlypathogenic avian influenza (HPAI)H5N1viruses is important
or evaluation of its potential to transmit to humans.1 Such tests
eed to be reliable, safe and amenable to high throughput imple-
entation. At present, the haemagglutination inhibition (HI) and
he micro-neutralization (MN) tests are available for this purpose.2Please cite this article in press as: Garcia J-M, et al. Optimization and eva
serological assay. J Clin Virol (2009), doi:10.1016/j.jcv.2009.10.009
he HI test is useful in serological studies of mammalian viruses
n mammalian species or of avian viruses infecting avian species.
owever, the conventional HI test is not sufficiently sensitive or
pecific for detecting antibody responses of humans infected with
Abbreviations: HPAI, highly pathogenic avian influenza; MN, micro-
eutralization; BSL, biosafety level; H5, haemagglutinin of H5N1 HPAI virus;
5pp, H5 pseudotyped viral particles; HI, haemagglutination inhibition assay; RT-
CR, reverse transcription polymerase chain reaction; HA, haemagglutinin; MDCK,
adin–Darby canine kidney; DMEM, Dulbecco modified Eagle medium; RLU, rel-
tive luminescence unit; ROC curve, receiver operating characteristic curve; CI,
onfidence interval; AUC, area under curve; SE, standard error; “c”, closest-to-(0,1)
riterion; “J”, Youden index; PPV, positive predictive value; NPV, negative predictive
alue; NA, neuraminidase.
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386-6532/$ – see front matter © 2009 Published by Elsevier B.V.
oi:10.1016/j.jcv.2009.10.009liable and safe alternative for sero-diagnosis and sero-epidemiology of
ting.
© 2009 Published by Elsevier B.V.
avian influenzaviruses althoughanadaptationusinghorseerythro-
cytes does make the test more useful.3,4 MN, which remains the
“gold standard” serological test for HPAI H5N1 at present, requires
access to the live virus and to biosafety level (BSL)-3 facilities.
While reverse genetics can be used to generate H5-viruses that are
safe enough to be used in BSL-2 conditions, such viruses require
intensive safety evaluation for non-pathogenicity in chickens and
ferrets before release for use in a BSL-2 setting.5 This limits its
widespread applicability of MN tests for those without access to
BSL-3 facilities. Recently we introduced a BSL-2 H5 haemagglu-
tinin pseudotyped lentiviral particle (H5pp) based assay.6 These
pseudoparticles can be produced using synthetic genes based on
virus haemagglutinin (HA) sequence data, even when there is no
access to live virus or viral cDNA. PseudotypingwithHAonly allows
us to detect the functional neutralizing antibody response to the
H5 without contribution from cross-reacting neuraminidase antis-
era. While others have also evaluated H5pp serological assays, they
have not described an analysis of the parameters that affect assay
performance.7,8 Moreover, their test validation has been based on
small numbers of sera.luation of an influenza A (H5) pseudotyped lentiviral particle-based
2. Objectives
Here we optimise H5pp assay, assess its reproducibility and
define its performance characteristics using sera frompatientswith
virologically confirmed H5N1 disease.
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Fig. 1. Optimization of virus dose in H5 pseudotype assay. Neutralization titers
threshold of a serum dilution of ≥20 (Fig. 3). Furthermore, 50% sig-ARTICLEModelCV-1848; No.of Pages5
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. Study design
.1. Serum samples
Controls sera were from healthy Hong Kong residents (106 chil-
ren, 102 adults and 118 persons >60 years of age) with no known
xposure to H5N1 influenza. The “positive” test panel was 41 sera
rom 10 patients with RT-PCR confirmed H5N1 disease collected
uring the outbreak in 2003/2004 in South Vietnam from days
to 784 after disease onset at the Hospital for Tropical Disease
f Ho Chi Minh City, Vietnam. The individual clinical details of
hese patients have been previously described in references.9–11
urthermore, Supplementary Material Table S1 gives correspon-
ence of patient ID number within the cited references to the
era tested in this evaluation. A pool of avian influenza H5 vacci-
ated chicken sera (MN titre 640) was used to optimize viral input
nd assess the reproducibility of the assay. A set of 15 subtyping
olyclonal hyperimmunized chicken antisera provided by Office
nternational des Epizooties (OIE) Reference Laboratory (Veteri-
ary Laboratory Agency, Surrey, UK) was used for testing subtype
pecificity.
.2. H5pp assay
H5pp were produced as described previously using codon opti-
ized H5 gene from A/Cambodia/408008/05 H5N1.6 Two-fold
erial dilutions of heat inactivated (56 ◦C, 30min) serum were
ixed with an equal volume of H5pp in culture medium (Dul-
ecco modified Eagle medium (DMEM) supplemented with 2.5%
oetal bovine serum (Invitrogen) 1%penicillin–streptomycin (Invit-
ogen)) corresponding to the dose that generates 105 RLU (or
therwisementioned) in standardized conditions, incubated for 2h
t 37 ◦C and then added to a preformedmonolayer ofMadin–Darby
anine kidney (MDCK) cells. After 48h incubation, luminescence
as read after addition of Steady-Glo (Promega) luciferase sub-
trate with either Micro-beta (PerkinElmer) or Glomax (Promega)
late readers. The neutralization of infection was detected by mea-
uring the reduction of end-point signal versus controls done in
bsence of serum or in absence of virus, regarded as equivalent to
% or 100% neutralization, respectively.
.3. Micro-neutralization test (MN)
The micro-neutralization test was done as described
reviously.12 One hundred tissue culture infectious dose 50
100 TCID50) of A/Vietnam/1194/04 (H5N1) virus was mixed with
n equal volume of 2-fold serial dilutions of serum in quadrupli-
ate, incubated for 1h at 37 ◦C and the virus antibody mixture
as added to a preformed monolayer of MDCK cells. The plates
ere incubated for 3 days and the cytopathic effect read under
n inverted microscope. Virus back titrations were included to
onfirm whether the challenge dose was as expected.
.4. Determination of neutralizing titer
In MN assay, titer was defined by the reciprocal highest serum
ilution protecting ≥50% of the wells. In H5pp assay, the recipro-
al dilution giving 50% (unless otherwise specified) neutralizationPlease cite this article in press as: Garcia J-M, et al. Optimization and eva
serological assay. J Clin Virol (2009), doi:10.1016/j.jcv.2009.10.009
as computed from the neutralization curved fitted with the Hill
quation.13 This takes into consideration information from all dilu-
ions anddoes not overly rely on fewquadruplicate serumdilutions
o determine the titer for a 50% effect as is done using the Reed and
uench method.14plotted against the input of H5pp expressed as log value of signal in relative lumi-
nescence unit (RLU) measured in absence of sera. Values represent the mean of
duplicates.
3.5. Determination of diagnostic parameters
A detailed description of the computation and interpreta-
tion these parameters (sensitivity, specificity, positive or negative
predictive values (PPV or NPV) and accuracy) can be found in
references.15,16
3.6. Statistical analysis
Bland–Altman analysis was used to evaluate the systematic
bias and limits of agreement of H5pp versus MN.17 The log-
transformation of titers was required for a normal distribution,
an assumption of the statistical test used, verified using normal
(quantile–quantile) plot (datanot show).All calculationsweredone
in ExcelTM.
4. Results
4.1. Determination of optimal amount of H5pp
In 33 independent experiments, we measured the titer of a
single pooled chicken serum for different batches of H5pp (mean
values of duplicate were used for the calculations). We found that
once the H5pp input exceeds around 105 RLU, the titer is relatively
independent of the H5pp concentration used (Fig. 1).
4.2. Determination of optimal cut-offs
The receiver operating characteristic (ROC) curve was used
for determination of optimal cut-off point.18 It was generated by
plotting the sensitivity as a function of 1-specificity (Fig. 2A).19
The optimal diagnostic effectiveness was determined using the
sensitivity/specificity that gives either the minimal value for
(1− sensitivity)2 + (1− specificity)2, called the “closest-to-(0,1)”
criterion, denoted “c”; or the maximal value for (sensitiv-
ity + specificity−1), theYouden Index,20 denoted “J”.We computed
ROC curves, “c” and “J” criteria using the panel of human sera by
simultaneously varying the positivity threshold (range [10–640])
and the percentage of neutralization (range [5–95%]) used to define
the titer. Both criteria identify the same optimal cut-off values
corresponding to 50% neutralization (Fig. 2B) and to positivityluation of an influenza A (H5) pseudotyped lentiviral particle-based
nal reduction is the value for which fitting using the Hill equation
is the most robust (inflection point). These ROC curves also indi-
cate that the assay has excellent accuracy as estimated by the area
under curve (AUC>0.99)with a corresponding standard errors (SE)
of <0.5%.21
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Fig. 2. Determination of optimal neutralization cut-off for titer calculation in H5pp assay using (A) ROC curve, (B) Youden index “J” (triangle, vertical left axis) and closest-












iig. 3. (A) Scatter plot of titers measured by H5pp or MN assay for a panel of 326 “Co
0 (first dilution tested 1:20). Dotted lines mark positivity titers of ≥20 and ≥80. (B)
ilution giving 50% neutralization.
.3. Assay reproducibility
The pooled chicken serum and a single batch of H5pp were used
o assess the reproducibility of the assay over 3 batches (tested on
different weeks) of 3 plates, each containing 6 replicates. Coef-Please cite this article in press as: Garcia J-M, et al. Optimization and eva
serological assay. J Clin Virol (2009), doi:10.1016/j.jcv.2009.10.009
cients of variation (CV%) were CVintra-plate < 5%, CVinter-plate < 3%
nd CVinter-batch < 7%.22 All variances calculated were homogenous
ccording to Cochran test at the level of significance ˛=0.05.
ig. 4. (A) Plot of titers measured with H5pp versus MN assays. (B) Bland–Altman scatter
ata, excluded fromanalysis (titer <20 in eithermethod), are plotted in (A) against the othe
n dotted line).negative and 41 “positive” human sera. Negative (<20) sera were given the value of
tion of “c” (B) and “J” (C) parameters for different positivity cut-off. Titer: reciprocal
4.4. Agreement of titers measured with H5pp or MN tests in
human sera
Titers measured with H5pp are higher than with the MN test
(Fig. 4A) suggesting a higher sensitivity in detecting H5 antibody.luation of an influenza A (H5) pseudotyped lentiviral particle-based
Using the statistical method developed by Bland and Altman,17 we
found that H5pp titers exceed the MN titers on average by 2-fold
(95% CI: 1.5–2.5) (p=0.002).
plot showing the systematic bias and the limits of agreement with 95% CI. Circled
rmethod probable range of values in agreement (continuous lines, 95% CI extension
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Table 1
Diagnostic parameters of H5pp and MN assays using a comprehensive panel of 244 “control” and 41 “positive” human sera for different positivity titers (reciprocal dilution
giving 50% neutralization). AUC: area under curve of the corresponding ROC curvewith standard error (SE); in an ideal assay: “J” = 1 and “c” = 0. Positive and negative predictive
values are noted PPV and NPV, respectively.
Positivity cut-off H5pp assay MN assay Screening with H5pp and confirming
those with H5pp titers ≥20 by MN test
≥80 ≥40 ≥20 ≥80 ≥40 ≥20 ≥80a ≥40a ≥20a
Sensitivity 90% 93% 95% 85% 95% 98% 83% 90% 93%
Specificity 99% 98% 97% 100% 100% 100% 100% 100% 100%
PPV 90% 86% 81% 100% 100% 98% 100% 100% 97%
NPV 99% 99% 99% 98% 99% 100% 98% 99% 99%
Accuracy 98% 98% 97% 98% 99% 99% 98% 99% 99%
Closest-to-(0,1), c 0.010 0.006 0.003
Youden index, J 0.89 0.91 0.92
AUC (SE) 0.994 (0.36%) 0.995 (0.34%) 0.995 (0.33%)
a Positivity cut-off in confirmatory MN assay.
Table 2
Subtype specificity of H5pp using an OIE panel of reference hyper-immune chicken
antisera.


































and NA) tests indicates that the HA plays a dominant role in theH12N5 A/Duck/Alberta/60/76 <20
H14N6 A/Mallard/Gurjev/244/82 <20
H16N3 A/Gull/Denmark/68110/02 <20
.5. Performance characteristics of the H5pp and MN assays on
uman serum panels
Using the optimized H5pp assay parameters, we compared
he H5pp assay with MN at different cut-off titres for positivity
Table 1). At the positivity threshold ≥80 defined by WHO,1 the
erformance of the H5pp test compares favourably with MN. At a
ower cut-off titer (≥20), the sensitivity of the H5pp test improves
from 90% to 95%) while the specificity drops (from 99% to 97%).
In the 326 control sera, 317 sera were negative in both assays.
ine hadH5pp titers≥20 (one also had anMN titer of 20) and seven
f these were from those over 60 years of age. When a titer of ≥80
as used as cut-off, 4 sera remained H5pp positive (Fig. 3A). In the
ositive panel of 41 sera, the H5pp and MN tests yield 4 and 6 false
egative sera, respectively at a cut-off of ≥80; while 2 and 1 sera,
espectively, remain false negative at a titer of ≥20. The latter MN
ata is comparable to a previous study on naturally infected H5N1
atient.23
.6. Subtype specificity
Using the panel of hyper-immune sera to 14 influenza virus
ubtypes (H13 and H15 were not available), we confirmed lack of
ross-reaction to non-H5 subtypes (Table 2).Please cite this article in press as: Garcia J-M, et al. Optimization and eva
serological assay. J Clin Virol (2009), doi:10.1016/j.jcv.2009.10.009
. Discussion
WeoptimizedandevaluatedaH5pseudoparticle-basedassayas
n alternative to the existingMNmethod for detection of neutraliz-
ng antibodies against the potentially pandemicH5 avian influenza.We established that increasing quantities of H5pp led to progres-
sive reduction of the antibody titer until the latter reaches or
exceeds around 105 RLU equivalents per well, beyond which point
the H5pp antibody titer becomes independent of the input H5pp
virus. Keeping the H5pp value above 105 RLU minimises batch-to-
batch variations in the antibody titers. It should be noted that the
numerical value of luminescence is dependent on the plate reader
used (“relative” luminescence unit) as each machine has different
signal amplification gain. Therefore, this threshold limit may have
to be re-optimized if a different plate reader is used.
We assessed the H5pp assay using a test panel of 326 control
sera from the general population in Hong Kong considered as true
negative and 41 sera from patients with virologically confirmed
H5N1 disease as true positive. An optimal positivity titer thresh-
old of 20 was found to maximise both sensitivity and specificity.
However the internationally accepted positivity cut-off titer in the
MN assay for H5N1 is defined as 80 to minimise the frequency of
false-positive results. We have therefore analysed our data at both
cut-off antibody levels. Most “false-positive” sera identified in the
H5pp testwere thoseover60yearsof age. It isnowrecognised that a
proportion of elderly persons have neutralizing antibodies to H5N1
virus.24 In that regard, the current panel of sera for test evaluation
is particularly stringent because 36% of the control panel are >60
years of age. At a positive cut-off titer of ≥80, the H5pp test com-
pares favourablywith theMN test. The specificity and PPV (Table 1)
of the H5pp test will be higher in those younger than 60 years of
age (i.e. 99% and 97%, respectively, data not shown).
Alternatively, an effective application of the H5pp test would be
to use it as a high throughput screening assay at BSL-2 containment
with the sera with titers ≥20 being confirmed in a reference BSL-
3 laboratory setting with the MN titer ≥80. Such a strategy leads
to diagnostic performances that are not markedly inferior to that
obtained by screening all the sera in BSL-3 containment using the
MN test (Table 1). This approach has major advantages in laborato-
ries with no access to BSL-3, including many developing countries
that are in the front-line in confronting HPAI H5N1 infection.
H5pp can bemade to carry the virusHA alone or to have bothHA
and NA. While the latter is technically easier to produce (unpub-
lished data) we have chosen to produce pseudotyped particles
that only contain the HA to have the opportunity to eliminate
some potential cross-subtype reactivity that may arise between for
example the NA of H5N1 and of the seasonal influenza virus H1N1.
The strong positive correlation we find between titers obtained
with the H5pp (only HA present) and MN (complete virus with HAluation of an influenza A (H5) pseudotyped lentiviral particle-based
neutralizing antibody response.
In conclusion,wehave developed and evaluated a high through-
put screening assay that can be carried out in BSL-2 containment.
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hat the H5pp assay faithfully replicates the results with the MN
est. Therefore, H5pp assay can be a safer alternative to MN for
onitoring the neutralizing antibody levels in applications such
s sero-epidemiological investigation of avian influenza or H5N1
elated vaccine immunity assessment.
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